

# Patient Card

## JEMPERLI (dostarlimab)



### Reminder information for patients taking JEMPERLI

**JEMPERLI may cause side effects that can sometimes become serious or life-threatening and can lead to death. Side effects may happen at any time during treatment or after treatment has ended. You may experience side effects in more than one body part at the same time.**

Contact your specialist immediately if you have any of the listed symptoms or any symptoms not listed on this card, or if symptoms worsen. **Prompt medical treatment may keep the problem from becoming more serious.** Your doctor may provide other medicines to treat your symptoms, withhold the next dose of JEMPERLI, or stop treatment.

#### **IMPORTANT**

- Do not attempt to diagnose or treat side effects yourself
- **Keep this card with you at all times**, including when travelling, going to the Accident and Emergency department, or seeing another doctor
- Keep this card for at least 4 months after the last dose of JEMPERLI
- Notify any health care professional you see that you are being treated with JEMPERLI and show them this card

This booklet is to be kept in the doctor's consultation room and to be given only by doctors to patients prescribed with JEMPERLI.

This card is produced as a service to patients by GlaxoSmithKline.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK group of companies or its licensor

For further information, please consult your doctor or pharmacist  
GlaxoSmithKline Pte Ltd, 23 Rochester Park, Singapore 139234

# Call your doctor if you have any of these signs or symptoms, any others, or if they get worse.

## Lungs

- Shortness of breath
- Chest pain
- New or worse cough

## Intestines

- Diarrhoea or more frequent bowel movements
- Black, tarry, sticky stool; blood or mucus in stools
- Severe stomach pain or tenderness
- Feeling or being sick (nausea or vomiting)

## Liver

- Feeling or being sick (nausea or vomiting)
- Loss of appetite
- Pain on right side of the stomach
- Yellowing skin or whites of eyes
- Dark-coloured urine
- Bleeding or bruising more easily than normal

## Kidneys

- Changes in urine amount or colour
- Swelling ankles
- Loss of appetite
- Blood in urine

## Hormone glands

- Rapid heartbeat
- Weight loss or gain
- Increased sweating
- Hair loss
- Feeling cold
- Constipation
- Abdominal pain
- Deeper voice
- Muscle aches
- Dizziness or fainting
- Persisting or unusual headache

## Skin

- Rash, itching, dry skin, peeling or skin sores
- Ulcers in the mouth, nose, throat or genital area

## Eyes

- Changes in eyesight

## Other organs

- Severe or persistent muscle or joint pains
- Severe muscle weakness
- Swollen or cold hands or feet

These are not the only side effects of JEMPERLI. If you experience any side effects, talk to your doctor, pharmacist or nurse.

# Important Contact Information



Name of Specialist

Phone

After-hours Phone

My Name

My Phone

Name of Emergency Contact

Emergency Contact (Phone)

# Important Information for Health Care Providers



This patient is being treated with JEMPERLI which can cause immune-related adverse reactions that may appear any time during treatment or after treatment. Immune-related adverse reactions may occur in any organ or tissue and may affect more than one body system simultaneously. Assess patients for signs and symptoms of immune-related adverse reactions including but not limited to those listed on this card. Early diagnosis and appropriate management are essential to minimise any consequences of immune-related adverse reactions.

For suspected immune-related adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, JEMPERLI should be withheld or permanently discontinued and corticosteroids or other appropriate therapy administered.

Specific guidelines for managing immune-related adverse reactions are available in the Singapore Package Insert for JEMPERLI.

Consultation with an oncologist or other medical specialist may be helpful for the management of immune-related adverse reactions.

Please refer to the Singapore Package Insert for JEMPERLI for more information. For reporting of adverse events, please write to [sg.drugsafety@gsk.com](mailto:sg.drugsafety@gsk.com).

**This document has been approved by HSA as of 10-05-2024.**